Monopar Therapeutics · Brief

Next report

10 days

Nov 12 · before openest.Q3 FY26

Expected move

No implied move.

8 reportsHistory

—≥ implied

Nov 8 '24—▲+7.31%—

Mar 31 '25—▼−9.72%—

May 13 '25—▼−3.65%—

Aug 12 '25—▲+14.55%—

Q3 FY25—▲+5.36%—

Q1 FY26—▼−0.84%—

May 14 '26—▼−0.73%—

Q2 FY26—▲+0.38%—

quarterimplied−15%0+15%realized×

Q2 FY26—▲+0.38%—

May '26—▼−0.73%—

Q1 FY26—▼−0.84%—

Q3 FY25—▲+5.36%—

Aug '25—▲+14.55%—

May '25—▼−3.65%—

2 older reports

Mar '25—▼−9.72%—

Nov '24—▲+7.31%—

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Nov 12 report · est.

Bull2

95managers reporting a position in regulatory filings13F · Jun 30 '26

16managers whose positions make up most of reported value13F · Jun 30 '26

Bear2 of 4

3tracked funds holding MNPRN-PORT · Aug 31 '26

0.01%of iShares Russell 2000 ETF's assets, the largest tracked-fund weightN-PORT · Jun 30 '26

AI captions · Sep 16 '26once per report · top 2 per case

MNPR report session

No linked exposure.

No changes.

privateThesis 0 · Decisions 0 · Observations 0

No thesis.